Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
3-oxoacyl-[acyl-carrier-protein] synthase 3 (KAS III, FabH) is an enzyme that catalyzes the initial condensation step in the type II fatty acid synthesis (FAS II) pathway in bacteria and plant plastids. It uses acetyl-CoA and malonyl-ACP to form acetoacetyl-ACP, initiating fatty acid biosynthesis. As it is essential for bacterial cell membrane formation but absent in mammals, it represents a promising target for novel antibiotics.
Inhibition of bacterial fatty acid synthesis
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 3-oxoacyl-[acyl-carrier-protein] synthase 3 (KAS III).